Loading stock data…
TLX
$9.41+0.19 (+2.06%)
After Hours$9.22-0.19 (-2.02%)· Last close Jun 9
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Telix Pharmaceuticals Limited in the Healthcare sector is trading at $9.41 with a market capitalization of $3.2B. Wall Street consensus targets $20.78 (4 analysts), implying a +120.8% move over the next 12 months. The stock is currently 49% below its 52-week high of $18.49, remaining 2.3% above its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +120.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$9.41
Potential Downside
0%
Whystock Fair Value$9.41
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus4 analysts
Mean target$20.78+120.8%
Range$19.63 – $22.40
Fundamentals
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therape...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.19B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.65
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-
Volume
Today's trading volume
107,331
Recent News
ASX Growth Companies With Insider Ownership Up To 20%
As tensions in the Middle East escalate, Australian shares are poised to open lower, reflecting global market jitters and concerns over an economic slowdown. In this uncertain environment, growth companies with high insider ownership can offer a unique perspective on potential resilience and alignment of interests between management and shareholders.
Is Telix (ASX:TLX) Quietly Assembling a Connected Oncology Platform That Reshapes Its Moat?
Telix Pharmaceuticals recently reported completion of patient enrolment in its Phase 1 IPAX-2 study of TLX101-Tx for newly diagnosed glioblastoma, with no dose-limiting toxicities observed at the highest tested dose, while also entering letters of intent to explore PSMA PET imaging collaborations in prostate cancer. These developments highlight Telix’s attempt to build a connected oncology platform, pairing LAT1-targeted brain cancer therapy with PSMA-guided, image-based treatment workflows...
Insider Buying: Telix Pharmaceuticals Co-Founder Bought US$997k Of Shares
Those following along with Telix Pharmaceuticals Limited ( ASX:TLX ) will no doubt be intrigued by the recent purchase...
How TLX597-Tx Phase 2 Dosimetry Data Will Impact Telix Pharmaceuticals (ASX:TLX) Investors
Earlier this week, Telix Pharmaceuticals reported Phase 2 OPTIMAL-PSMA trial dosimetry results for its second-generation prostate cancer candidate TLX597-Tx, showing low radiation uptake in key non-target organs and supporting further evaluation in earlier-stage disease. The data suggest TLX597-Tx may allow higher treatment doses while limiting toxicity, potentially expanding access to lutetium-based therapy across more prostate cancer patients and geographies. We’ll now explore how these...
Telix Pharmaceuticals Webinar Highlights Next-Gen PSMA Therapy, OPTIMAL-PSMA Enrollment Nears End
Telix Pharmaceuticals (NASDAQ:TLX) hosted an educational webinar outlining its next-generation prostate-specific membrane antigen (PSMA) radiopharmaceutical strategy, with management and a clinical investigator emphasizing the need for more patient-centric dosing and improved tolerability as PSMA-ta